Beacon Financial Advisory’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$838K Hold
699
0.17% 165
2026
Q1
$643K Buy
699
+60
+9% +$60.8K 0.15% 185
2025
Q4
$687K Buy
639
+165
+35% +$158K 0.16% 168
2025
Q3
$362K Buy
474
+39
+9% +$29K 0.08% 256
2025
Q2
$339K Buy
435
+63
+17% +$49K 0.09% 259
2025
Q1
$307K Buy
372
+92
+33% +$76.6K 0.09% 240
2024
Q4
$216K Buy
280
+8
+3% +$6.62K 0.07% 273
2024
Q3
$241K Buy
272
+37
+16% +$33.3K 0.08% 253
2024
Q2
$212K Sell
235
-45
-16% -$36K 0.08% 263
2024
Q1
$218K Buy
+280
New +$199K 0.11% 224

Other funds holding LLY

Beacon Financial Advisory's LLY Position: Q2 2026 in Review

Beacon Financial Advisory held its Eli Lilly (LLY) position steady in Q2 2026 at 699 shares worth $838K. The position accounts for 0.17% of the portfolio, ranked #165.

Beacon Financial Advisory first reported a position in LLY in Q1 2024 and has held it in 10 quarters since. 4,633 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Beacon Financial Advisory held 699 shares of Eli Lilly worth $838K as of Q2 2026.
  • Beacon Financial Advisory left its Eli Lilly share count unchanged in Q2 2026.
  • Eli Lilly made up 0.17% of Beacon Financial Advisory's portfolio in Q2 2026, its #165 holding.
  • Beacon Financial Advisory first reported a position in Eli Lilly in Q1 2024 and has held it in 10 quarters since.
  • 4,633 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Beacon Financial Advisory's 13F filing for Q2 2026, filed 5 Aug 2026.